Mazindol CR meets in Phase II to treat ADHD

NLS Pharma Group (Stans, Switzerland) reported data from the double-blind, U.S. Phase II NLS-1001 trial in 85 adults with ADHD showing that once-daily mazindol CR (NLS-1) met the primary endpoint of improving the mean change in total ADHD-RS-DSM-5 score from baseline to week 6 vs. placebo (18.9 vs. 5.7 points, p<0.001). Mazindol CR also met the secondary endpoint of a greater proportion of patients achieving a ≥50% reduction in ADHD-RS-DSM-5 score at day 14 vs. placebo. Additionally, a significantly greater proportion of patients who received mazindol CR achieved a ≥30% (70% vs. 21.1%, p<0.001) and a ≥50% (55% vs. 15.8%, p=0.002) reduction in ADHD-RS-DSM-5 score at week 6 vs. placebo. Clinical Global Improvement (CGI) scale score was also a secondary endpoint...